Top Insights
Health
globalreutersNovember 25, 20241 Mins read
FDA Nod for BridgeBio Brings New Competition to Blockbuster Pfizer Cardio Drug
globalreutersNovember 25, 20241 Mins read 
BridgeBio Pharma claims its drug, Attruby, has an edge over a Pfizer drug as a treatment for cardiomyopathy caused by transthyretin-mediated amyloidosis. But new competition to both products could come soon from Alnylam Pharmaceuticals, now set to receive an FDA decision in this indication by late March.
The post FDA Nod for BridgeBio Brings New Competition to Blockbuster Pfizer Cardio Drug appeared first on MedCity News.
Related Articles
What is HEMA?
The Pink Sheet reports on a new international health technology assessment (HTA)...
Long COVID: When Recovery Feels Out of Reach
Long COVID is just more than simple fatigue and health changes for...
How Pending Health-Related Lawsuits Could be Impacted by the Incoming Trump Administration
This brief provides an overview of current lawsuits in health policy including...
Pediatric Cardiac Surgery in India: A Guide for Parents
15 million, You heard it right this is the number of children...
Leave a comment